Navigation Links
Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
Date:5/15/2013

lication. However, this technology that allows "regeneration of damaged organs" has been hindered from benefiting the general public due to the scientific scam by Dr. Yamanaka, depriving the chances of tens of thousands of patients for getting access to innovative science and technology for cures.

The scientific route of "developing drugs to regenerate damaged organs" has been labeled one of the nation's main topics of focus, and was also discussed by president Obama in his 2013 State of the Union Address, where he stated "Now, if we want to make the best products, we also have to invest in the best ideas. Every dollar we invested to map the human genome returned $140 to our economy. Every dollar. Today, our scientists are mapping the human brain to unlock the answers to Alzheimer's. We're developing drugs to regenerate damaged organs, devising new materials to make batteries 10 times more powerful. Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race. We need to make those investments."

Dr. Xu is thankful for the Obama administration's acknowledgement of this vital area of organ regeneration, and feels that this direction is a blessing for Americans and people worldwide.

Please contact Jane Westgate 336.608.4439 or Cheryl Riley 703.683.1798. The Plaintiff is represented by the Ardent Law Group in California.


'/>"/>
SOURCE Mebo International; Ardent Law Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
2. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
3. Enbrel® (etanercept) Patent Issued
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
6. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
7. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
8. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Texas , July 27, 2015 ... Market by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, ... , Europe , Asia-Pacific ... to 2019", The global biopreservation media market was valued at ... around $571.5 million by 2019, at a CAGR of 18.2% ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, ... than 8,000 clinics have submitted over 100,000 specimens to ... in just the first 10 days since the breakthrough ... disease (CKD) is a leading cause of suffering and ... submitted specimens are consistent with generally accepted kidney disease ...
(Date:7/25/2015)... ... , ... Technology leader Anton Paar offers the Abbemat ... temperature of the measuring prism. This is required to achieve the most precise ... key requirements. It is likely that no refractometer manufacturers on the market can ...
(Date:7/24/2015)... NEW YORK , July 24, 2015 ... the following equities: PDL BioPharma Inc. (NASDAQ: PDLI ... Inc. (NASDAQ: STEM ), Northwest Biotherapeutics Inc. (NASDAQ: ... ACOR ). Free research report on PDL BioPharma can ... 23, 2015, the NASDAQ Composite ended at 5,146.41, down ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3